热门期刊: 细胞研究(英文版)、 中华医学杂志(英文版)、国际临床研究杂志 等
艾司西酞普兰对青少年抑郁症患者抑郁症状改善效果及安全性观察
Efficacy and safety of escitalopram in improving depressive symptoms in adolescent patients with depression
ES评分0
DOI | |
刊名 |
Journal of International Psychiatry
|
年,卷(期) | 2022, 49(2) |
作者 |
乔兴菊*,
|
作者单位 |
河南省洛阳荣康医院心身疾病少儿科 ; |
摘要 |
【摘要】目的:分析艾司西酞普兰治疗青少年抑郁症的临床效果及安全性。方法:选定本院2018年8月至2020年8月收治的110例青少年抑郁症患者,根据“治疗方法的不同”分组,参照组55例患者采纳舍曲林治疗,观察组55例患者采纳艾司西酞普兰治疗,两组临床疗效均在治疗8周后评价,比较两组临床疗效、HAMD评分、不良反应发生率、SCL-90评分。结果:观察组临床总有效率(94.55%)高于参照组(74.07%),观察组治疗后HAMD评分、SCL-90评分均低于参照组,差异均具有统计学意义(P<0.05)。观察组不良反应发生率(5.45%)与参照组(5.56%)比较,差异无统计学差异(P>0.05)。结论:艾司西酞普兰可有效改善青少年抑郁症患者抑郁症状,提高生存质量,且不良反应较少。
[Abstract] Objective: to analyze the clinical effect and safety of escitalopram in the treatment of adolescent depression. Methods: 110 patients with adolescent depression treated in our hospital from August 2018 to August 2020 were selected according to "different treatment methods" 55 patients in the reference group were treated with sertraline and 55 patients in the observation group were treated with escitalopram. The clinical efficacy of the two groups were evaluated after 8 weeks of treatment. The clinical efficacy, HAMD score, incidence of adverse reactions and SCL-90 score of the two groups were compared. Results: the total clinical effective rate of the observation group (94.55%) was higher than that of the reference group (74.07%), and the HAMD score and SCL-90 score of the observation group were lower than those of the reference group (P<0.05). There was no significant difference in the incidence of adverse reactions between the observation group (5.45%) and the reference group (5.56%) (P>0.05). Conclusion: Escitalopram can effectively improve the depressive symptoms and quality of life of adolescent patients with depression, with less adverse reactions.
|
关键词 |
【关键词】艾司西酞普兰;青少年;抑郁症;临床疗效;安全性
【 key words 】 escitalopram; adolescents; depression; clinical efficacy; safety
|
基金项目 | |
页码 | 220-222 |